Cell Therapy Company Announces Approval For Heart Failure Treatment Study

BioCardia's CardiAMP Cell Therapy: A Groundbreaking Development in Heart Failure Treatment.

As an investor it's important to stay updated with major news. Get real-time stock market alerts, news, and research by creating an account here.

In a significant development for the field of cardiovascular disease treatment, BioCardia, Inc. (NASDAQ: BCDA), a leader in innovative, autologous cell therapies, announced the Centers for Medicare & Medicaid S…